Last updated on September 2017

A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors


Brief description of study

This study will examine the safety profile of SGN-2FF. The study will test increasing doses of SGN-2FF given daily to small groups of patients.

Detailed Study Description

This study will examine the safety profile of SGN-2FF given orally to patients with advanced solid tumors. Patients may continue treatment until progression of their disease or intolerable side effects. The primary goal of the study is to identify the optimal biological dose that does not exceed the maximum tolerated dose (MTD). The pharmacokinetics (PK) and antitumor activity of SGN-2FF will also be evaluated in the study.

Clinical Study Identifier: NCT02952989

Contact Investigators or Research Sites near you

Start Over

Francisco Robert, MD

University of Alabama at Birmingham
Birmingham, AL United States
  Connect »

Karen Reckamp, MD

City of Hope National Medical Center
Duarte, CA United States
  Connect »

Ross Camidge

University of Colorado Hospital / University of Colorado
Aurora, CO United States
  Connect »

Conor Steuer, MD

Winship Cancer Institute / Emory University School of Medicine
Atlanta, GA United States
  Connect »

Khanh Do, MD

Dana Farber Cancer Institute
Boston, MA United States
  Connect »

Amy Weise, MD

Karmanos Cancer Institute / Wayne State University
Detroit, MI United States
  Connect »

Martin Gutierrez

Hackensack University Medical Center
Hackensack, NJ United States
  Connect »

Rachel Sanborn, MD

Providence Portland Medical Center
Portland, OR United States
  Connect »

Howard Burris

Sarah Cannon Research Institute
Nashville, TN United States
  Connect »

Timothy Yap, MD

MD Anderson Cancer Center / University of Texas
Houston, TX United States
  Connect »

Laura Chow

Seattle Cancer Care Alliance / University of Washington
Seattle, WA United States
  Connect »